Russell Investments Group Ltd. Sells 76,565 Shares of AbbVie Inc. $ABBV

Russell Investments Group Ltd. trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 4.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,544,550 shares of the company’s stock after selling 76,565 shares during the period. Russell Investments Group Ltd. owned about 0.09% of AbbVie worth $404,308,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Ariadne Wealth Management LP boosted its holdings in AbbVie by 3.0% in the 3rd quarter. Ariadne Wealth Management LP now owns 5,730 shares of the company’s stock worth $1,499,000 after acquiring an additional 165 shares during the period. Tortoise Investment Management LLC grew its position in AbbVie by 9.0% in the third quarter. Tortoise Investment Management LLC now owns 1,229 shares of the company’s stock valued at $321,000 after acquiring an additional 101 shares in the last quarter. Everest Financial Group LLC grew its position in AbbVie by 5.0% in the third quarter. Everest Financial Group LLC now owns 3,801 shares of the company’s stock valued at $994,000 after acquiring an additional 182 shares in the last quarter. Werba Rubin Papier Wealth Management raised its stake in shares of AbbVie by 7.5% during the third quarter. Werba Rubin Papier Wealth Management now owns 4,543 shares of the company’s stock valued at $1,188,000 after purchasing an additional 317 shares during the period. Finally, Van Strum & Towne Inc. raised its stake in shares of AbbVie by 1.2% during the third quarter. Van Strum & Towne Inc. now owns 38,213 shares of the company’s stock valued at $9,996,000 after purchasing an additional 440 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Down 0.1%

Shares of ABBV opened at $294.75 on Friday. The firm has a market cap of $521.01 billion, a price-to-earnings ratio of 50.73, a PEG ratio of 1.34 and a beta of 0.20. The business’s 50 day moving average is $274.82 and its two-hundred day moving average is $240.55. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $302.93.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.86 earnings per share. On average, equities analysts expect that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. AbbVie’s payout ratio is currently 119.10%.

Analyst Ratings Changes

ABBV has been the topic of a number of recent research reports. Argus boosted their target price on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Bank of America reaffirmed a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Cantor Fitzgerald boosted their price objective on shares of AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a report on Monday, November 2nd. BNP Paribas Exane upped their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Finally, Oppenheimer raised their target price on AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $297.46.

Insiders Place Their Bets

In other news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Latest AbbVie News

Here’s some of the latest news about ABBV:

• Positive Sentiment: AbbVie’s immunology sales rose 16.6% in the third quarter, with Skyrizi and Rinvoq growth more than offsetting Humira’s decline. The performance has supported higher 2026 sales expectations and strengthens the case that newer drugs can sustain growth. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Positive Sentiment: AbbVie recently raised its 2026 revenue guidance to about $67.8 billion and increased its dividend after reporting third-quarter revenue of $17.4 billion. These updates reinforce the company’s earnings and shareholder-return outlook. Can AbbVie Justify Its Valuation After Raised Guidance and Strong Results?
• Neutral Sentiment: A Crohn’s disease study update drew coverage describing its likely near-term stock impact as limited; it does not appear to materially change the immediate investment outlook. AbbVie Crohn’s Disease Study Update

AbbVie Company Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.